Boston Scientific lowers full-year revenue outlook as restructuring plan targets slowing growth

Boston Scientific announced on July 29 that it is cutting its 2026 full-year organic revenue growth forecast to 5-6%, down from the prior 6.5-8% range.

The revision follows a second consecutive quarter of lowered guidance, reflecting a tougher outlook for the next six months.

CEO Michael Mahoney cited competitive pressure in electrophysiology and a sharp slowdown in the Watchman heart-implant business, which fell from about 30% growth last year to just over 4% in Q2.

The company has already begun a restructuring effort that includes job cuts and cost-saving measures, and Mahoney warned that these headwinds could extend into the following year.

Despite beating sales expectations earlier, the firm expects the second half to be more pressured than originally anticipated.